Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response includes some label-supported statements about rash/hypersensitivity and infections, but many rash severity/timing characteristics and clinician management details are not supported by the provided label excerpts; it also adds an emergency trigger (fever with rapidly spreading rash) that is not present in the provided label text.
Category Scores
Accurate Statements
Humira (adalimumab) can cause skin reactions, including rashes.
Supported: hypersensitivity reactions include rash; postmarketing skin reactions reported. (5.3; 6.3)
Humira-related rashes can include redness, itching, bumps, hives, or worsening of existing skin conditions.
Partially/mostly supported by label examples of hypersensitivity skin findings (rash/urticaria) and postmarketing skin reactions including new or worsening psoriasis; 'fixed drug reaction' and other rash types are mentioned. (5.3; 6.3)
Seek urgent care or emergency help if a rash comes with trouble breathing.
Supported as severe hypersensitivity symptoms warrant immediate medical attention; anaphylaxis/serious allergic reactions are described. (5.3; 17)
Seek urgent care or emergency help if a rash comes with swelling of the face or throat.
Supported by labeling of angioneurotic edema and immediate medical attention for severe hypersensitivity reactions. (5.3; 17)
Seek urgent care or emergency help if a rash includes blistering or peeling skin.
Supported by postmarketing skin reactions including Stevens Johnson Syndrome and other severe skin reactions reported; severe hypersensitivity guidance supports urgent attention for severe manifestations. (6.3; 17)
Humira can trigger new rashes.
Supported by postmarketing skin reactions including 'new or worsening psoriasis' and hypersensitivity reactions such as rash. (5.3; 6.3)
Humira can worsen existing skin conditions.
Supported by postmarketing 'new or worsening psoriasis' and worsening skin reactions. (6.3)
Humira can cause flares of inflammatory skin diseases during treatment.
Partially supported via postmarketing 'new or worsening psoriasis' (inflammatory skin disease). (6.3)
Humira can present with infections that include skin findings.
Supported in concept: HUMIRA increases risk of serious infections and patients should contact doctor for symptoms of infection; severe infections can involve skin findings (label does not enumerate 'skin findings' explicitly in provided excerpts, but infection counseling supports infection-related serious illness). (5.1; 17)
Humira can lower immune responses.
Supported explicitly in patient counseling: HUMIRA may lower the ability of the immune system to fight infections. (17)
Some rashes are caused by infections in people taking Humira, including fungal or viral skin infections.
Partially supported: label supports risk of invasive fungal infections and viral infections (as part of serious infections/infection counseling), but the excerpt does not explicitly state 'skin infections' for fungal/viral. (5.1; 17)
Humira rash management may include considering switching treatment if rash is more severe or clearly linked to Humira.
Partially supported: label instructs to discontinue HUMIRA if an anaphylactic or other serious allergic reaction occurs; 'fixed drug reaction' and other hypersensitivity reactions are reported. (5.3)
If the clinician suspects Humira is responsible, they may document it, treat symptoms, and consider stopping or changing therapy if necessary.
Partially supported: discontinuation and appropriate therapy for serious allergic reactions is stated, but 'document it' is not explicitly stated. (5.3)
If infection is suspected, clinicians may order tests or start appropriate antimicrobial treatment.
Partially supported: label advises prompt and complete diagnostic workup and initiate appropriate antimicrobial therapy for new infection during treatment. (5.1)
Unsupported Statements
Humira-related rashes can range from mild irritation to more serious reactions.
Provided excerpts do not describe mild-to-severe range for rashes.
Seek urgent care or emergency help if a rash comes with fever and rapidly spreading rash.
No such specific emergency trigger is present in the provided label excerpts.
Humira can cause new eruptions during treatment.
Postmarketing includes 'new or worsening psoriasis,' but 'new eruptions' wording for general rash eruptions is not explicitly supported in the provided excerpts.
New or unusual rashes during Humira treatment should be evaluated promptly.
No explicit 'evaluate promptly' instruction for rashes is present in the provided excerpts.
Rashes can occur after starting or restarting Humira due to immune changes after starting a biologic.
No restart/immune-change mechanism details are present in the provided excerpts.
Rashes after starting or restarting Humira can be due to relapses or emergence of skin conditions influenced by immune signaling.
No mechanism/relapse/immune signaling explanation is present in the provided excerpts.
Some reactions appear soon after initiation or after dose changes.
No timing-by-initiation/dose-change statement is present in the provided excerpts.
Some reactions can develop later.
No timing latency statement is present in the provided excerpts.
A clinician may recommend symptomatic care for mild rashes.
No symptomatic care recommendation for mild rashes is present in the provided excerpts.
A clinician may recommend dose adjustment for rash.
No dose adjustment guidance for rash is present in the provided excerpts.
Infection-related rashes often look different from typical drug rashes.
No comparative description of rash appearance is present.
Infection-related rashes may be associated with fever, sores, or crusting.
No such specific association is present.
Infection-related rashes may require close examination before deciding next steps.
The excerpt supports diagnostic workup for new infection, but does not provide 'close examination of rash' as a specific rash-management instruction.
A clinician may ask about the rash start date relative to Humira dosing.
No structured history-taking instructions are present.
A clinician may ask whether a rash is itchy, painful, blistering, or spreading.
No such checklist is present in the provided excerpts.
A clinician may ask about new medications, supplements, or recent infections.
No such history prompts are present.
A clinician may ask about fever, swollen lymph nodes, or other symptoms.
No such specific symptom-elicitation list is present.
Dermatology referral is common if the rash is persistent, atypical, or severe.
No 'dermatology referral is common' guidance is present.
Contradictions
Important Omissions
No mention that, for serious allergic/hypersensitivity reactions, HUMIRA should be immediately discontinued and appropriate therapy instituted (anaphylaxis/angioneurotic edema guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most rash-related content is consistent with hypersensitivity/infection risk themes, but multiple rash-management specifics are not supported by the provided label excerpts, and one added emergency trigger ('fever and rapidly spreading rash') is not present in the provided labeling, which could misdirect emphasis.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several specific rash-timing/mechanism and clinician-management recommendations are not supported by the provided label excerpts; one emergency trigger is not supported.
Suggested Improvement
Restrict rash-related urgent-care and management statements to those explicitly present in the provided label text (e.g., immediate medical attention for severe hypersensitivity symptoms; discontinuation/appropriate therapy for serious allergic reactions; infection-risk counseling), and remove unsupported specifics not found in the excerpts.